Article thumbnail

Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid

By Cheryl A. Luis, Laila Abdullah, Ghania Ait-Ghezala, Benoit Mouzon, Andrew P. Keegan, Fiona Crawford and Michael Mullan


We examined the usefulness of brief neuropsychological tests and serum Aβ as a predictive test for detecting MCI/AD in older adults. Serum Aβ levels were measured from 208 subjects who were cognitively normal at enrollment and blood draw. Twenty-eight of the subjects subsequently developed MCI (n = 18) or AD (n = 10) over the follow-up period. Baseline measures of global cognition, memory, language fluency, and serum Aβ1–42 and the ratio of serum Aβ1–42/Aβ1–40 were significant predictors for future MCI/AD using Cox regression with demographic variables, APOE ε4, vascular risk factors, and specific medication as covariates. An optimal sensitivity of 85.2% and specificity of 86.5% for predicting MCI/AD was achieved using ROC analyses. Brief neuropsychological tests and measurements of Aβ1–42 obtained via blood warrants further study as a practical and cost effective method for wide-scale screening for identifying older adults who may be at-risk for pathological cognitive decline

Topics: Research Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2011). A .W e s t o n ,N .R .G r a ff-Radford et al., “Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline,”
  2. (2009). a n dM .M .B u d g e ,“ D e t e c t i o no fM C Ii nt h ec l i n i c :e v a l u a t i o n of the sensitivity and specificity of a computerised test battery, the Hopkins verbal learning test and the MMSE,” Age and Ageing,
  3. (2009). Alzheimer’s disease anti-inflammatory prevention trial: design, methods and baseline results,”
  4. (2007). Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer’ disease,”
  5. (1999). B o n d i ,D .P .S a l m o n ,D .G a l a s k o ,R .G .T h o m a s ,a n d L.J.Thal,“Neuropsychological functionand apolipoproteinE genotype in the preclinical detection of Alzheimer’s disease,”
  6. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease,”
  7. (2009). CSF biomarkers and incipient Alzheimer’ disease in patients with mild cognitive impairment,”
  8. (2001). Current concepts in mild cognitive impairment,”Archives of Neurology,
  9. (2000). Dementia diagnoses from clinical and neuropsychological data compared: the cache county study,”
  10. (1983). Development and validation of a geriatric depression screening scale: a preliminary report,”
  11. (2009). e m u r i ,H .J .W i s t e ,S .D .W e i g a n de ta l .
  12. (2009). Early identification and treatment of Alzheimer’s disease: social and fiscal outcomes,”
  13. (1997). Expanded norms for the controlled oral word association test,”
  14. (1975). F o l s t e i n ,S .E .F o l s t e i n ,a n dP .R .M c H u g h ,“ M i n im e n t a l state. A practical method for grading the cognitive state of patients for the clinician,”
  15. (2007). Fluctuations of CSF amyloid-β levels: implications for a diagnostic and therapeutic biomarker,”
  16. (2007). Forecasting the global burden of Alzheimer’s disease,”
  17. (2009). High serum Aβ and vascular risk factors in first-degree relatives of Alzheimer’s disease patients,”
  18. (2004). Imaging brain amyloid in Alzheimer’sdisease with pittsburgh compound-B,”
  19. (2006). L.M.Ercoliet al.,“PET ofbrain amyloid and tau in mild cognitive impairment,”
  20. (2008). Le Goff,X .M i l l e te ta l . ,“ P r o d r o m a l Alzheimer’s disease: successive emergence of the clinical symptoms,”
  21. (2008). Long-term effects of Abeta42 immunisationin Alzheimer’s disease: follow-up of a randomized, placebo-controlled phase 1 trial,”
  22. M.Holtzman,“Cerebrospinal fluid tau/β-amyloid(42) ratioasaprediction ofcognitivedeclineinnondementedolder adults,”ArchivesofNeurology,vol.64,no.3,pp.343–349,2007.
  23. (1979). Memory complaints after electroconvulsive therapy: assessment with a new self-rating scale instrument,”
  24. (2009). Monitoring the amyloid beta-peptide in vivo—caveat emptor,”
  25. (1994). Multilingual Aphasia Examination, AJA Associates,
  26. (2007). Naproxen and celecoxib do not prevent AD in early results from a randomizedclinicaltrial,”Neurology,vol.68,no.21,pp.1800– 1808,
  27. (2007). Neuropsychological measures in normal individuals that predict subsequent cognitive decline,”
  28. (2008). Onset of Alzheimer’s dementia occurs commonly without prior cognitive impairment: results from the Alzheimer’s disease anti-inflammatory prevention trial (ADAPT)
  29. (1999). P e t e r s e n ,G .E .S m i t h ,S .C .W a r i n g ,R .J .I v n i k
  30. (2007). Patterns of atrophy differ among specific subtypes of mild cognitive impairment,”
  31. (1996). Performance of the dementia severity rating scale: a caregiver questionnairefor rating severity
  32. (2008). Plasma amyloid β protein is elevated in late-onset Alzheimer’ disease families,”
  33. Plasma beta-amyloid and cognitive decline,” Archives of Neurology.
  34. (1995). Predictors of cognitive change in middle-aged and older adults with memory loss,”
  35. (1996). Revision of the brief visual spatial memory tests: studies of normal performance,reliabilityandvalidity,”PsychologicalAssessment,
  36. (2009). Serum Aβ levels as predictors ofconversionto mildcognitiveimpairment/Alzheimer d i s e a s ei na nA D A P Ts u b c o h o r t ,
  37. (2009). Serum β-amyloid correlates with neuropsychological impairment,”
  38. (1991). Shipley Institute of Living Scale—Revised,W e s t e r n Psychological Services,
  39. (1982). Symbol Digit Modalities Test—Manual,W e s t e r n Psychological Services,
  40. (2009). Tenyear change in plasma amyloid β levels and late-life cognitive decline,”
  41. (1989). The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease,”
  42. (1989). The development and validation of a test battery for detecting and monitoring everyday memory problems,”
  43. (1991). The Hopkins verbal learning test: development ofa newmemorytest with sixequivalent forms,”
  44. (2007). The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels,”
  45. (2009). The influence of matrix type, diurnal rhythm and sample collectionandprocessingonthemeasurementofplasmabetaamyloid isoforms using the INNO-BIA plasma Abeta forms multiplex assay,”
  46. (1987). The modified mini-mental state (MMS) examination,”
  47. (1986). Trail Making Test: Manual for Administering and Scoring,
  48. (1981). Wechsler Adult Intelligence Scale—Revised.
  49. (1987). Wechsler Memory Scale—Revised, Psychological Corporation,
  50. (2008). β-amyloid is associated with reduced cognitive function in healthy older adults,”